source
- Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran failNovartis CEO Vas Narasimhan has insisted that the phase 3 fail for del-desiran is just a “bump” in the Swiss pharma’s wider plans for the drug, despite costing the company an estimated $1.9 billion.
- GSK's B7-H3 ADC cuts osteosarcoma progression risk by 67% in Chinese phase 3 trialA phase 3 study in China evaluated GSK's B7-H3‑directed antibody‑drug conjugate, risvutatug rezetecan (ris‑rez), in patients with relapsed osteosarcoma. The trial met its primary endpoint, showing…